United States - English - NLM (National Library of Medicine)

physicians group llc - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - hand sanitizer to help reduce bacteria that potentially can cause disease. for use when soap and water are not available.

United States - English - NLM (National Library of Medicine)

physicians wellness group inc - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - hand sanitizer to help reduce bacteria that potentially cause disease. for use when soap and water are not available.

United States - English - NLM (National Library of Medicine)

physicians group llc - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - hand sanitizer to help reduce bacteria that potentially can cause disease. for use when soap and water are not available.

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

amgen south africa (pty)ltd - infusion (parenteral) - see ingredients - each vial contains blinatumomab 38,5 ug

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p) - alendronic acid 10 mg - alendronate sodium tablets are indicated for: - treatment and prevention of osteoporosis in postmenopausal women for the treatment of osteoporosis, alendronate sodium tablets increase bone mass and reduce the incidence of fractures, including those of the hip and spine (vertebral compression fractures). osteoporosis may be confirmed by the finding of low bone mass (for example, at least 2 standard deviations below the premenopausal mean) or by the presence or history of osteoporotic fracture (see clinical pharmacology , pharmacodynamics ). for the prevention of osteoporosis, alendronate sodium tablets may be considered in postmenopausal women who are at risk of developing osteoporosis and for whom the desired clinical outcome is to maintain bone mass and to reduce the risk of future fracture. bone loss is particularly rapid in postmenopausal women younger than age 60. risk factors often associated with the development of postmenopausal osteoporosis include early menopause; moderately low bone mass (for examp

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (sodium cation - unii:lyr4m0nh37), sodium phosphate, dibasic anhydrous (unii: 22ado53m6f) (sodium cation - unii:lyr4m0nh37) - sodium cation 1.102 g - osmoprep tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. osmoprep tablets are contraindicated in patients with biopsy-proven acute phosphate nephropathy. osmoprep tablets are contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients. laxatives and purgatives (including osmoprep) have the potential for abuse by bulimia nervosa patients who frequently have binge eating and vomiting.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - indomethacin (unii: xxe1cet956) (indomethacin - unii:xxe1cet956) - indomethacin 25 mg - carefully consider the potential benefits and risks of indomethacin capsules and other treatment options before deciding to use indomethacin. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). indomethacin has been found effective in active stages of the following: - moderate to severe rheumatoid arthritis including acute flares of chronic disease. - moderate to severe ankylosing spondylitis. - moderate to severe osteoarthritis. - acute painful shoulder (bursitis and/or tendinitis). - acute gouty arthritis. indomethacin is contraindicated in patients with known hypersensitivity to indomethacin or the excipients (see description). indomethacin should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic/anaphylactoid reactions to nsaids have been reported in such patients (see warnings: anaphylactic/anaphylactoid reactions, and pr

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - ketorolac tromethamine (unii: 4eve5946bq) (ketorolac - unii:yzi5105v0l) - ketorolac tromethamine 10 mg - carefully consider the potential benefits and risks of ketorolac tromethamine and other treatment options before deciding to use ketorolac tromethamine. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals. ketorolac tromethamine tablets are indicated for the short-term (≤ 5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. therapy should always be initiated with ketorolac tromethamine-iv or im and ketorolac tromethamine tablets are to be used only as continuation treatment, if necessary. the total combined duration of use of ketorolac tromethamine-iv/im and ketorolac tromethamine tablets is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see warnings, precautions, dosage and administration and adverse reactions). patients should be switched to alternative anal

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 100 mg - carefully consider the potential benefits and risks of diclofenac sodium extended-release and other treatment options before deciding to use diclofenac sodium extended-release. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). diclofenac sodium extended-release tablets are indicated: • for relief of signs and symptoms of osteoarthritis • for relief of signs and symptoms of rheumatoid arthritis diclofenac sodium extended-release tablets are contraindicated in patients with known hypersensitivity to diclofenac. diclofenac sodium extended-release should not be given to patients who have experienced asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings, anaphylactoid reactions, and precautions, preexisting asthma). diclofenac sodium extended-release is contraindicated for the treatment of

Australia - English - Department of Health (Therapeutic Goods Administration)

market australia inc - ascorbic acid,calcium carbonate,calcium citrate hydrate,calcium lactate pentahydrate,calcium phosphate,calcium sulfate,cholecalciferol,magnesium carbonate - heavy,magnesium oxide,manganese sulfate monohydrate,potassium citrate,riboflavine -